All In Biotech

Drug Trial Radar · NCT07481747

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,539 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,539

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Feb 14, 2027

Study completion Mar 17, 2028

Sponsor

Lead sponsor
Hudson BiotechIndustry
Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.

Conditions

  • Obesity
  • Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

Interventions

  • TirzepatideDrug

    (once-weekly SC injection; doses 5/10/15 mg)

  • PlaceboDrug

    (once-weekly SC injection)

  • Reduced-calorie dietBehavioral

    increased physical activity counseling

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change in body weight from randomizationTime frame: 72 Weeks
  2. Percentage of participants achieving ≥5% body weight reduction from randomizationTime frame: 72 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.